Nonstimulant medication approved to treat attention-deficit/hyperactivity disorder

Article

FDA has approved the first nonstimulant medication that can be used either conjunctively with psychostimulant medications or as monotherapy to treat attention-deficit/hyperactivity disorder in children and adolescents aged 6 to 17 years.

FDA has approved the first nonstimulant medication that can be used either conjunctively with psychostimulant medications or as monotherapy to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years.

Clonidine extended-release tablets (Kapvay; Shionogi Inc) contain centrally acting alpha2-adrenergic agonists that stimulate receptors in the brain stem, reducing sympathetic outflow from the central nervous system and decreasing peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Taken twice daily, clonidine improves core ADHD symptoms in this age group when also used as part of a treatment program that includes other psychological, educational, and social measures.

In clinical trials, the most common adverse effects in adjunctive therapy were sleepiness and sedation compared with placebo, so physicians should consider accumulative sedative effects before prescribing clonidine for use with active depressants such as phenothiazines, barbiturates, or benzodiazepines.

Related Videos
Discussing health care sustainability, climate change, and WHO's One Health goal | Image credit: Provided by Shreya Doshi
Willough Jenkins, MD
Screening for and treating the metatarsus adductus foot deformity |  Image Credit: UNFO md ltd
Wendy Ripple, MD
Wendy Ripple, MD
Courtney Nelson, MD
DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: © Marija - © Marija - stock.adobe.com.
Carissa Baker-Smith
Perry Roy, MD
© 2024 MJH Life Sciences

All rights reserved.